KPRX Stock Overview
A clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Kiora Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.23 |
| 52 Week High | US$8.98 |
| 52 Week Low | US$3.00 |
| Beta | -0.29 |
| 11 Month Change | -7.45% |
| 3 Month Change | -12.70% |
| 1 Year Change | -32.11% |
| 33 Year Change | -99.41% |
| 5 Year Change | -99.88% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem
May 21
Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Kiora Pharmaceuticals reports 1H results
Aug 12Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing
Jul 28Kiora Pharmaceuticals prices $5.2M underwritten public offering
Jul 22Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Jul 05EyeGate Pharmaceuticals announces $8M private placement
Jan 06EyeGate surge in premarket as it acquires Panoptes Pharma for $4M
Dec 21Shareholder Returns
| KPRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -6.1% | -5.3% | -1.2% |
| 1Y | -32.1% | 8.7% | 30.4% |
Return vs Industry: KPRX underperformed the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: KPRX underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| KPRX volatility | |
|---|---|
| KPRX Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KPRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KPRX's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 12 | Brian Strem | www.kiorapharma.com |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair.
Kiora Pharmaceuticals, Inc. Fundamentals Summary
| KPRX fundamental statistics | |
|---|---|
| Market cap | US$9.59m |
| Earnings (TTM) | US$5.55m |
| Revenue (TTM) | US$16.02m |
1.7x
P/E Ratio0.6x
P/S RatioIs KPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KPRX income statement (TTM) | |
|---|---|
| Revenue | US$16.02m |
| Cost of Revenue | US$4.83m |
| Gross Profit | US$11.19m |
| Other Expenses | US$5.64m |
| Earnings | US$5.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 69.86% |
| Net Profit Margin | 34.64% |
| Debt/Equity Ratio | 0% |
How did KPRX perform over the long term?
See historical performance and comparison